Αποτελέσματα Αναζήτησης
At Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of circulating tumor DNA in plasma. Boreal’s OnTarget...
One of the major successes of Genome BC’s Technology Development platform is Boreal Genomics, a spin-off company started in 2007 by co-director and UBC researcher Dr. Andre Marziali and colleagues. In 2004 Dr. Marziali co-invented a patented technology to purify nucleic acids.
www.borealgenomics.com
Formed in 2007, Boreal Genomics is among a cohort of UBC spin-off companies that helped grow the momentum of biomedical innovation in British Columbia. The company developed innovative research tools and diagnostic tests for early detection and monitoring of cancer patients, attracting more than $20 million in investment and at its peak ...
The company's platform performs genomic analysis of cell-free DNA in plasma to detect and quantify mutations in tumor-derived circulating nucleic acids, thereby enabling healthcare professionals to get accurate tumor profiling and real-time monitoring of tumor evolution.
11 Ιουλ 2024 · The electrophoretic technique is being commercialized through Boreal Genomics, a UBC spin-off company, and is expected to have broad applications from basic life-science research to forensic sample analysis, bio-defence and pathogen detection for food safety and clinical diagnostics.
21 Μαρ 2017 · For Vancouver’s Boreal Genomics, home proved a better bet than Silicon Valley. Andre Marziali's biotech company started with a machine invented in a basement suite that could clean up DNA samples. Then his team developed a blood test for cancer
